Study details
Enrolling now
Lofexidine and Buprenorphine for PTSD and Opioid Relapse
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
NCT IDNCT04360681ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
120
Study length
about 4.8 years
Ages
18–70
Locations
2 sites in TX
About this study
Researchers are testing if lofexidine, taken with buprenorphine, helps reduce symptoms of both opioid use disorder and post-traumatic stress disorder in veterans. The trial will compare the safety and effectiveness of buprenorphine alone versus buprenorphine plus lofexidine.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lofexidine
- 2.Take Placebo oral tablet
PhasePhase 2
DrugLofexidine
Routeoral
Primary goalOpioid Use
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
lofexidine
Drug routes
oral (Oral Tablet), oral
Endpoints
Primary: Opioid Use, PTSD Symptoms (Checklist)
Secondary: PTSD Symptoms
Body systems
Psychiatry / Mental Health